器械检测心房颤动合并血管疾病患者的抗凝治疗:NOAH-AFNET 6与ARTESiA试验联合分析
该研究对NOAH-AFNET 6(n=2534)和ARTESiA(n=4012)试验进行预设分析,比较器械检测心房颤动(DDAF)患者伴或不伴血管疾病时抗凝与不抗凝的疗效与安全性。伴血管疾病患者抗凝后主要复合终点事件率较低,不伴血管疾病者两组事件率相等;抗凝在两类患者中均增加大出血。
要点
- DDAF合并血管疾病患者血栓栓塞及心血管事件风险更高,抗凝可能获益更大。
- DDAF不合并血管疾病患者抗凝与不抗凝的主要疗效终点事件率相等。
- 抗凝在伴或不伴血管疾病的DDAF患者中均增加大出血风险。
核心结论
- DDAF合并血管疾病患者卒中及心血管事件风险更高,可能从抗凝治疗中获益大于不合并血管疾病者。
研究设计与样本
- 预设分析纳入NOAH-AFNET 6(n=2534例)和ARTESiA(n=4012例)两项随机试验,比较DDAF患者伴或不伴血管疾病时抗凝与不抗凝的结局。
- 血管疾病定义为既往卒中/短暂性脑缺血发作、冠状动脉或外周动脉疾病。
主要发现
- 伴血管疾病者(NOAH-AFNET 6占56%,ARTESiA占46%),抗凝组与不抗凝组的主要疗效复合终点(卒中、体循环动脉栓塞、心肌梗死、肺栓塞或心血管死亡)事件率分别为3.9%/患者年 vs 5.0%/患者年(NOAH-AFNET 6)和3.2%/患者年 vs 4.4%/患者年(ARTESiA)。
- 不伴血管疾病者,抗凝与不抗凝的主要疗效复合终点事件率相等(NOAH-AFNET 6为2.7%/患者年;ARTESiA两组均为2.3%/患者年)。
临床怎么用
- 对DDAF合并血管疾病患者,应评估抗凝治疗以降低卒中及心血管事件风险,同时警惕大出血风险增加。
- 对DDAF不合并血管疾病患者,抗凝获益不明显且增加出血,需个体化决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The optimal antithrombotic therapy in patients with device-detected atrial fibrillation (DDAF) is unknown. Concomitant vascular disease can modify the benefits and risks of anticoagulation. METHODS: These pre-specified analyses of the NOAH-AFNET 6 (n = 2534 patients) and ARTESiA (n = 4012 patients) trials compared anticoagulation with no anticoagulation in patients with DDAF with or without vascular disease, defined as prior stroke/transient ischaemic attack, coronary or peripheral artery disease. Efficacy outcomes were the primary outcomes of both trials, a composite of stroke, systemic arterial embolism (SE), myocardial infarction, pulmonary embolism or cardiovascular death, and stroke or SE. Safety outcomes were major bleeding or major bleeding and death. RESULTS: In patients with vascular disease (NOAH-AFNET 6, 56%; ARTESiA, 46%), stroke, myocardial infarction, systemic or pulmonary embolism, or cardiovascular death occurred at 3.9%/patient-year with and 5.0%/patient-year without anticoagulation (NOAH-AFNET 6), and 3.2%/patient-year with and 4.4%/patient-year without anticoagulation (ARTESiA). Without vascular disease, outcomes were equal with and without anticoagulation (NOAH-AFNET 6, 2.7%/patient-year; ARTESiA, 2.3%/patient-year in both randomized groups). Meta-analysis found consistent results across both trials (I2heterogeneity = 6%) with a trend for interaction with randomized therapy (pinteraction = .08). Stroke/SE behaved similarly. Anticoagulation equally increased major bleeding in vascular disease patients [edoxaban, 2.1%/patient-year; no anticoagulation, 1.3%/patient-year; apixaban, 1.7%/patient-years; no anticoagulation, 1.1%/patient-year; incidence rate ratio 1.55 (1.10-2.20)] and without vascular disease [edoxaban, 2.2%/patient-year; no anticoagulation, 0.6%/patient-year; apixaban, 1.4%/patient-year; no anticoagulation, 1.1%/patient-year; incidence rate ratio 1.93 (0.72-5.20)]. CONCLUSIONS: Patients with DDAF and vascular disease are at higher risk of stroke and cardiovascular events and may derive a greater benefit from anticoagulation than patients with DDAF without vascular disease.
引用
- Schnabel, Benezet-Mazuecos, Becher, et al. Anticoagulation in device-detected atrial fibrillation with or without vascular disease: a combined analysis of the NOAH-AFNET 6 and ARTESiA trials. Eur Heart J. 2024. PMID: 39222018. doi:10.1093/eurheartj/ehae596
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。